Hyperuricemia, disease activity, and 10-year cardiovascular risk in chronic inflammatory arthritis: a post-hoc analysis of the CARMA project

Clicks: 15
ID: 339796
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #64 of 77 articles by views in international journal of rheumatology

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Abstract
OBJECTIVES: To determine the prognostic impact of hyperuricemia on cardiovascular events and its association with inflammatory markers and disease activity in patients with chronic inflammatory arthritis (CIA). METHODS: Post-hoc analysis of a 10-year prospective cohort (2010-2022) including 1,552 patients with CIA and 349 controls from 67 Spanish hospitals. Hyperuricemia was defined as serum urate (SU) >6.8 mg/dL at baseline, and its impact on major adverse cardiovascular events (MACE) during follow-up was assessed using multivariable logistic regression. Associations of hyperuricemia and SU levels with inflammatory markers and individual (swollen joint count, tender joint count, global VAS) and composite disease activity indices (DAS28, BASDAI) were analyzed using Pearson correlation and Mann-Whitney U test. RESULTS: Hyperuricemia prevalence was 11.2% in both CIA and controls, with a mean serum urate level of 5.0 ± 2.3 in the CIA group and 5.0 ± 1.4 in controls. Hyperuricemia independently increased the risk of MACE in CIA (adjusted OR 1.87, 95% CI 1.23-2.86), particularly in axial spondyloarthritis (adjusted OR 4.02, 95% CI 1.96-8.24), but not in rheumatoid arthritis or psoriatic arthritis; SU levels were not predictive. Hyperuricemia correlated with higher hsCRP levels in axial spondyloarthritis, psoriatic arthritis, and controls, but not in rheumatoid arthritis. No associations were found with ESR or disease activity indices. CONCLUSION: Baseline hyperuricemia is an independent prognostic factor for cardiovascular events in CIA, particularly in axial spondyloarthritis, but not in non-inflammatory controls. It was also associated with higher hsCRP levels, without any effect on disease activity indices. Individualized management strategies are needed in CIA.
Reference Key
openalex_W7225987917 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors
Journal international journal of rheumatology
Year 2026
DOI
10.1093/rheumatology/keag641
URL
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

No comments yet. Be the first to comment on this article.